This trial tests a combination of two medications, atomoxetine and oxybutynin, in children with Down syndrome and sleep apnea. The goal is to see if these medications can improve their breathing during sleep over several months. The study will measure changes in sleep quality and overall health. Atomoxetine is a nonstimulant medication used for ADHD and generally has fewer negative effects on sleep compared to other treatments.